{"denoms":[{"counts":[{"groupId":"BG000","value":"216"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"429"}],"units":"Participants"}],"groups":[{"description":"Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.","id":"BG000","title":"Octreotide+ Everolimus"},{"description":"Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.","id":"BG001","title":"Octreotide+ Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.72","value":"60.1"},{"groupId":"BG001","spread":"11.13","value":"59.4"},{"groupId":"BG002","spread":"10.92","value":"59.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"208"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"221"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}